Biomaterials for the treatment of alzheimer's disease

Frontiers in Bioengineering and Biotechnology

Volumn 4, Issue JUN, 2016, Pages

  Hadavi, Darya ^a   Poot, André A ^a  

^a UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Alzheimer's disease; Biomaterials; Delivery systems; Liposomes; Nanoparticles; Scaffolds

Indexed keywords

BIOMATERIALS; DISEASE CONTROL; LIPOSOMES; NANOPARTICLES; NEURODEGENERATIVE DISEASES; SCAFFOLDS; SCAFFOLDS (BIOLOGY);

ALZHEIMER'S DISEASE; BLOOD-BRAIN BARRIER; CURRENT TREATMENTS; DELIVERY ROUTES; DELIVERY SYSTEMS; LATEST DEVELOPMENT; THERAPEUTIC AGENTS; THERAPEUTIC COMPOUNDS;

DISEASES;

EID: 85012205249     PISSN: None     EISSN: 22964185     Source Type: Journal    
DOI: 10.3389/fbioe.2016.00049     Document Type: Review

References (71)

1. Adlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier, E., Robb, E., Cortes, M., et al. (2008). Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 59, 43-55. doi:10.1016/j.neuron.2008.06.018
2. Alzheimer's Association. (2012). Alzheimer's disease facts and figures. Alzheimers Dement. 8, 131-168. doi:10.1016/j.jalz.2012.02.001
3. Anand, R., Gill, K. D., and Mahdi, A. A. (2014). Therapeutics of Alzheimer's disease: past, present and future. Neuropharmacology 76(Pt A), 27-50. doi:10.1016/j.neuropharm.2013.07.004
4. Ansari, M. A., Abdul, H. M., Joshi, G., Opii, W. O., and Butterfield, D. A. (2009). Protective effect of quercetin in primary neurons against Abeta(1-42): relevance to Alzheimer's disease. J. Nutr. Biochem. 20, 269-275. doi:10.1016/j.jnutbio.2008.03.002
5. Armstrong, R. A. (2014). A critical analysis of the 'amyloid cascade hypothesis'. Folia Neuropathol. 3, 211-225. doi:10.5114/fn.2014.45562
6. Armstrong, R. A. (2013). Review article what causes Alzheimer's disease? Folia Neuropathol. 51, 169-188. doi:10.5114/fn.2013.37702
7. Arumugam, K., Subramanian, G. S., Mallayasamy, S. R., Averineni, R. K., Reddy, M. S., and Udupa, N. (2008). A study of rivastigmine liposomes for delivery into the brain through intranasal route. Acta Pharm. 58, 287-297. doi:10.2478/v10007-008-0014-3
8. Ballabh, P., Braun, A., and Nedergaard, M. (2004). The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis. 16, 1-13. doi:10.1016/j.nbd.2003.12.016
9. Beduneau, A., Saulnier, P., and Benoit, J. P. (2007). Active targeting of brain tumors using nanocarriers. Biomaterials 28, 4947-4967. doi:10.1016/j.biomaterials.2007.06.011
10. Blurton-Jones, M., Kitazawa, M., Martinez-Coria, H., Castello, N. A., Muller, F. J., Loring, J. F., et al. (2009). Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 106, 13594-13599. doi:10.1073/pnas.0901402106
11. Brookmeyer, R., Johnson, E., Ziegler-Graham, K., and Arrighi, H. M. (2007). Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 3, 186-191. doi:10.1016/j.jalz.2007.04.381
12. Brunholz, S., Sisodia, S., Lorenzo, A., Deyts, C., Kins, S., and Morfini, G. (2012). Axonal transport of APP and the spatial regulation of APP cleavage and function in neuronal cells. Exp. Brain Res. 217, 353-364. doi:10.1007/s00221-011-2870-1
13. Canovi, M., Markoutsa, E., Lazar, A. N., Pampalakis, G., Clemente, C., Re, F., et al. (2011). The binding affinity of anti-Abeta1-42 MAb-decorated nanoliposomes to Abeta1-42 peptides in vitro and to amyloid deposits in post-mortem tissue. Biomaterials 32, 5489-5497. doi:10.1016/j.biomaterials.2011.04.020
14. Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., et al. (2001). Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30, 665-676. doi:10.1016/S0896-6273(01)00317-8
15. Citron, M. (2010). Alzheimer's disease: strategies for disease modification. Nat. Rev. Drug Discov. 9, 387-398. doi:10.1038/nrd2896
16. Cormier, A. R., Pang, X., Zimmerman, M. I., Zhou, H.-X., and Paravastu, A. K. (2013). Molecular structure of RADA16-I designer self-assembling peptide nanofibers. ACS Nano 7, 7562-7572. doi:10.1021/nn401562f
17. Cui, G. H., Shao, S. J., Yang, J. J., Liu, J. R., and Guo, H. D. (2016). Designer self-assemble peptides maximize the therapeutic benefits of neural stem cell transplantation for Alzheimer's disease via enhancing neuron differentiation and paracrine action. Mol. Neurobiol. 53, 1108-1123. doi:10.1007/s12035-014-9069-y
18. Cui, Z., Lockman, P. R., Atwood, C. S., Hsu, C.-H., Gupte, A., Allen, D. D., et al. (2005). Novel d-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. Eur. J. Pharm. Biopharm. 59, 263-272. doi:10.1016/j.ejpb.2004.07.009
19. Di Stefano, A., Iannitelli, A., Laserra, S., and Sozio, P. (2011). Drug delivery strategies for Alzheimer's disease treatment. Expert Opin. Drug Deliv. 8, 581-603. doi:10.1517/17425247.2011.561311
20. Eckert, G. P., Chang, S., Eckmann, J., Copanaki, E., Hagl, S., Hener, U., et al. (2011). Liposome-incorporated DHA increases neuronal survival by enhancing non-amyloidogenic APP processing. Biochim. Biophys. Acta 1808, 236-243. doi:10.1016/j.bbamem.2010.10.014
21. Folch, J., Petrov, D., Ettcheto, M., Pedrós, G., Abad, S., Beas-Zaratec, C., et al. (2015). Masitinib for the treatment of mild to moderate Alzheimer's disease. Expert Rev. Neurother. 15, 587-596. doi:10.1586/14737175.2015.1045419
22. Gao, N., Sun, H., Dong, K., Ren, J., and Qu, X. (2015). Gold-nanoparticle-based multifunctional amyloid-β inhibitor against Alzheimer's disease. Chemistry 21, 829-835. doi:10.1002/chem.201404562
23. Gobbi, M., Re, F., Canovi, M., Beeg, M., Gregori, M., Sesana, S., et al. (2010). Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide. Biomaterials 31, 6519-6529. doi:10.1016/j.biomaterials.2010.04.044
24. Gregoriadis, G. (2008). Liposome research in drug delivery: the early days. J. Drug Target. 16, 520-524. doi:10.1080/10611860802228350
25. Gu, H., Long, D., Song, C., and Li, X. (2009). Recombinant human NGF-loaded microspheres promote survival of basal forebrain cholinergic neurons and improve memory impairments of spatial learning in the rat model of Alzheimer's disease with fimbria-fornix lesion. Neurosci. Lett. 453, 204-209. doi:10.1016/j.neulet.2009.02.027
26. Gunawardena, S., and Goldstein, L. S. (2001). Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. Neuron 32, 389-401. doi:10.1016/S0896-6273(01)00496-2
27. Han, F., Wang, W., and Chen, C. (2015). Research progress in animal models and stem cell therapy for Alzheimer's disease. J. Neurorestoratol. 3, 11-12. doi:10.2147/jn.s74160
28. Hardy, J., and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease-progress and problems on the road to therapeutics. Science 297, 353-356. doi:10.1126/science.1072994
29. Holmes, T. C., de Lacalle, S., Su, X., Liu, G., Rich, A., et al. (2000). Extensive neurite outgrowth and active synapse formation on self-assembling peptide scaffolds. Proc. Natl. Acad. Sci. U.S.A. 97, 6728-6733. doi:10.1073/pnas.97.12.6728
30. Hölscher, C. (2014). New drug treatments show neuroprotective effects in Alzheimer's and Parkinson's diseases. Neural. Regen. Res. 9, 1870-1873. doi:10.4103/1673-5374.145342
31. Hunsberger, J. G., Rao, M., Kurtzberg, J., Bulte, J. W. M., Atala, A., LaFerla, F. M., et al. (2016). Accelerating stem cell trials for Alzheimer's disease. Lancet Neurol. 15, 219-230. doi:10.1016/s1474-4422(15)00332-4
32. Irwin, R. W., and Brinton, R. D. (2014). Allopregnanolone as regenerative therapeutic for Alzheimer's disease: translational development and clinical promise. Prog. Neurobiol. 113, 40-55. doi:10.1016/j.pneurobio.2013.08.004
33. Kim, D., and Tsai, L. H. (2009). Bridging physiology and pathology in AD. Cell 137, 997-1000. doi:10.1016/j.cell.2009.05.042
34. Kumar, A., Singh, A., and Ekavali. (2015). A review on Alzheimer's disease pathophysiology and its management: an update. Pharmacol. Rep. 67, 195-203. doi:10.1016/j.pharep.2014.09.004
35. Kurakhmaeva, K. B., Djindjikhashvili, I. A., Petrov, V. E., Balabanyan, V. U., Voronina, T. A., Trofimov, S. S., et al. (2009). Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J. Drug Target. 17, 564-574. doi:10.1080/10611860903112842
36. Lasagna-Reevesa, C., Gonzalez-Romeroa, D., Barriaa, M. A., Olmedoc, I., Closa, A., Ramanujamb, V. M. S., et al. (2010). Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice. Biochem. Biophys. Res. Commun. 393, 649-655. doi:10.1016/j.bbrc.2010.02.046
37. Lauzon, M. A., Daviau, A., Marcos, B., and Faucheux, N. (2015). Nanoparticle-mediated growth factor delivery systems: a new way to treat Alzheimer's disease. J. Control Release 206, 187-205. doi:10.1016/j.jconrel.2015.03.024
38. Li, Y., Liao, Y., Chang, H., and Young, T. (2013). Covalent bonding of GYIGSR to EVAL membrane surface to improve migration and adhesion of cultured neural stem/precursor cells. Colloids Surf. B Biointerfaces 102, 53-62. doi:10.1016/j.colsurfb.2012.08.054
39. Liu, G., Men, P., Harris, P. L., Rolston, R. K., Perry, G., and Smith, M. A. (2006). Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci. Lett. 406, 189-193. doi:10.1016/j.neulet.2006.07.020
40. Liu, G., Men, P., Kudo, W., Perry, G., and Smith, M. A. (2009). Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease. Neurosci. Lett. 455, 187-190. doi:10.1016/j.neulet.2009.03.064
41. Locatelli, E., and Franchini, M. C. (2012). Biodegradable PLGA-b-PEG polymeric nanoparticles: synthesis, properties, and nanomedical applications as drug delivery system. J. Nanopart. Res. 14, 1316. doi:10.1007/s11051-012-1316-4
42. Lockman, P. R., Oyewumi, M. O., Koziara, J. M., Roder, K. E., Mumper, R. J., and Allen, D. D. (2003). Brain uptake of thiamine-coated nanoparticles. J. Control. Release 93, 271-282. doi:10.1016/j.jconrel.2003.08.006
43. Lu, J., Zheng, Y. L., Luo, L., Wu, D. M., Sun, D. X., and Feng, Y. J. (2006). Quercetin reverses d-galactose induced neurotoxicity in mouse brain. Behav. Brain Res. 171, 251-260. doi:10.1016/j.bbr.2006.03.043
44. Modi, G., Pillay, V., Choonara, Y. E., Ndesendo, V. M., du Toit, L. C., and Naidoo, D. (2009). Nanotechnological applications for the treatment of neurodegenerative disorders. Prog. Neurobiol. 88, 272-285. doi:10.1016/j.pneurobio.2009.05.002
45. Mourtas, S., Canovi, M., Zona, C., Aurilia, D., Niarakis, A., La Ferla, B., et al. (2011). Curcumin-decorated nanoliposomes with very high affinity for amyloid-beta1-42 peptide. Biomaterials 32, 1635-1645. doi:10.1016/j.biomaterials.2010.10.027
46. Muhs, A., Hickman, D. T., Pihlgren, M., Chuard, N., Giriens, V., Meerschman, C., et al. (2007). Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 104, 9810-9815. doi:10.1073/pnas.0703137104
47. Mullane, K., and Williams, M. (2013). Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? Biochem. Pharmacol. 85, 289-305. doi:10.1016/j.bcp.2012.11.014
48. Musardo, S., Saraceno, C., Pelucchi, S., and Marcello, E. (2013). Trafficking in neurons: searching for new targets for Alzheimer's disease future therapies. Eur. J. Pharmacol. 719, 84-106. doi:10.1016/j.ejphar.2013.07.019
49. Mutlu, N. B., Degim, Z., Yilmaz, S., Eiz, D., and Nacar, A. (2011). New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations. Drug Dev. Ind. Pharm. 37, 775-789. doi:10.3109/03639045.2010.541262
50. Orive, G., Anitua, E., Pedraz, J. L., and Emerich, D. F. (2009). Biomaterials for promoting brain protection, repair and regeneration. Nat. Rev. Neurosci. 10, 682-692. doi:10.1038/nrn2685
51. Phachonpai, W., Wattanathorn, J., Muchimapura, S., Tong-Un, T., and Preechagoon, D. (2010). Neuroprotective effect of quercetin encapsulated liposomes: a novel therapeutic strategy against Alzheimer's disease. Am. J. Appl. Sci. 7, 480-485. doi:10.3844/ajassp.2010.480.485
52. Popovic, N., and Brundin, P. (2006). Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases. Int. J. Pharm. 314, 120-126. doi:10.1016/j.ijpharm.2005.09.040
53. Ranka, K. B., Pauleya, A. M., Bhattacharyaa, K., Wanga, Z., Evansa, D. B., Flecka, T. J., et al. (2002). Direct interaction of soluble human recombinant tau protein with Abeta 1-42 results in tau aggregation and hyperphosphorylation by tau protein kinase II. FEBS Lett. 514, 263-268. doi:10.1016/S0014-5793(02)02376-1
54. Ritchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., and Tammer, A. (2003). Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 60, 1685-1691. doi:10.1001/archneur.60.12.1685
55. Rogers, S., and Friedhoff, L. (1998). Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicenter open label extension study. Eur. Neuropsychopharmacol. 8, 67-75. doi:10.1016/S0924-977X(97)00079-5
56. Roney, C., Kulkarni, P., Arora, V., Antich, P., Bonte, F., Wu, A., et al. (2005). Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J. Control Release 108, 193-214. doi:10.1016/j.jconrel.2005.07.024
57. Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., et al. (2008). Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842. doi:10.1038/nm1782
58. Sinha, J., Das, N., and Basu, M. K. (2001). Liposomal antioxidants in combating ischemia-reperfusion injury in rat brain. Biomed. Pharmacother. 55, 264-271. doi:10.1016/S0753-3322(01)00060-9
59. Spuch, C., and Navarro, C. (2011). Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer's disease and Parkinson's disease). J. Drug Deliv. 2011, 469679. doi:10.1155/2011/469679
60. Sulheim, E., Baghirov, H., von Haartman, E., Boe, A., Aslund, A. K., Morch, Y., et al. (2016). Cellular uptake and intracellular degradation of poly(alkyl cyanoacrylate) nanoparticles. J. Nanobiotechnology. 14, 1. doi:10.1186/s12951-015-0156-7
61. Sun, L., Liu, S. Y., Zhou, X. W., Wang, X. C., Liu, R., Wang, Q., et al. (2003). Inhibition of protein phosphatase 2A-and protein phosphatase 1-induced tau hyperphosphorylation and impairment of spatial memory retention in rats. Neuroscience 118, 1175-1182. doi:10.1016/S0306-4522(02)00697-8
62. Thal, D. R., and Fandrich, M. (2015). Protein aggregation in Alzheimer's disease: a beta and tau and their potential roles in the pathogenesis of AD. Acta Neuropathol. 129, 163-165. doi:10.1007/s00401-015-1387-2
63. Thinakaran, G., and Koo, E. H. (2008). Amyloid precursor protein trafficking, processing, and function. J. Biol. Chem. 283, 29615-29619. doi:10.1074/jbc. R800019200
64. Thorne, R. G., Pronk, G. J., Padmanabhan, V., and Frey, W. H. (2004). Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127, 481-496. doi:10.1016/j.neuroscience.2004.05.029
65. Wattanathorn, J., Phachonpai, W., Pripem, S., and Suthiparinyanont, S. (2007). Intranasal administration of quercetin liposome decreases anxiety-like behaviour and increases spatial memory. Am. J. Agric. Biol. Sci. 2, 31-33. doi:10.3844/ajabssp.2007.31.35
66. Williams, D. F. (2009). On the nature of biomaterials. Biomaterials 30, 5897-5909. doi:10.1016/j.biomaterials.2009.07.027
67. Wilson, B. (2009). Brain targeting PBCA nanoparticles and the blood-brain barrier. Nanomedicine 4, 499-502. doi:10.2217/nnm.09.29
68. Yang, S., Leong, K.-F., Du, Z., and Chua, C.-K. (2001). The design of scaffolds for use in tissue engineering. Part I. Traditional factors. Tissue Eng. 7, 679-689. doi:10.1089/107632701753337645
69. Zhang, C., Chen, J., Feng, C., Shao, X., Liu, Q., Zhang, Q., et al. (2014a). Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer's disease. Int. J. Pharm. 461, 192-202. doi:10.1016/j.ijpharm.2013.11.049
70. Zhang, W., Wang, G. M., Wang, P. J., Zhang, Q., and Sha, S. H. (2014b). Effects of neural stem cells on synaptic proteins and memory in a mouse model of Alzheimer's disease. J. Neurosci. Res. 92, 185-194. doi:10.1002/jnr.23299
71. Zhang, P., Chen, L., Gu, W., Xu, Z., Gao, Y., and Li, Y. (2007). In vitro and in vivo evaluation of donepezil-sustained release microparticles for the treatment of Alzheimer's disease. Biomaterials 28, 1882-1888. doi:10.1016/j.biomaterials.2006.12.016